IWM
CNCR

IHT Wealth Management’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

IHT Wealth Management’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-750
Closed -$21K – 589
2018
Q1 		$21K Hold
750
– – 0.01% 951
2017
Q4 		$18K Buy
+750
New +$18.9K ﹤0.01% 1015

Other funds holding CNCR

BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

IHT Wealth Management's CNCR Position: Q2 2018 in Review

IHT Wealth Management sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q2 2018, closing a stake of 750 shares — an estimated $21K sold.

IHT Wealth Management first reported a position in CNCR in Q4 2017 and held it in 2 quarters. The position peaked at $21K in Q1 2018. 28 funds tracked by Wall St. Rank hold CNCR as of Q2 2018.

  • IHT Wealth Management reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q2 2018 after selling out during the quarter.
  • IHT Wealth Management sold 750 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2018, an estimated $21K.
  • IHT Wealth Management first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2017 and held it in 2 quarters.
  • IHT Wealth Management's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $21K in Q1 2018.
  • 28 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2018.

Based on IHT Wealth Management's 13F filing for Q2 2018, filed 13 Aug 2018.